KR20040066103A - 조합제제내에 비스포스포네이트, ｃｏｘ－２ 저해제 및탁솔을 포함하는, 악성 종양의 치료에 사용하기 위한 약학조성물 - Google Patents

조합제제내에 비스포스포네이트, ｃｏｘ－２ 저해제 및탁솔을 포함하는, 악성 종양의 치료에 사용하기 위한 약학조성물 Download PDF

Info

Publication number
KR20040066103A
KR20040066103A KR10-2004-7005630A KR20047005630A KR20040066103A KR 20040066103 A KR20040066103 A KR 20040066103A KR 20047005630 A KR20047005630 A KR 20047005630A KR 20040066103 A KR20040066103 A KR 20040066103A
Authority
KR
South Korea
Prior art keywords
cox
inhibitor
effective amount
taxol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7005630A
Other languages
English (en)
Korean (ko)
Inventor
알란 립톤
로이스 메리 위터스
조나단 그린
Original Assignee
노파르티스 아게
알란 립톤
로이스 메리 위터스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 알란 립톤, 로이스 메리 위터스 filed Critical 노파르티스 아게
Publication of KR20040066103A publication Critical patent/KR20040066103A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2004-7005630A 2001-10-19 2002-10-18 조합제제내에 비스포스포네이트, ｃｏｘ－２ 저해제 및탁솔을 포함하는, 악성 종양의 치료에 사용하기 위한 약학조성물 Ceased KR20040066103A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
US60/345,921 2001-10-19
PCT/EP2002/011696 WO2003035081A1 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol

Publications (1)

Publication Number Publication Date
KR20040066103A true KR20040066103A (ko) 2004-07-23

Family

ID=23357099

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7005630A Ceased KR20040066103A (ko) 2001-10-19 2002-10-18 조합제제내에 비스포스포네이트, ｃｏｘ－２ 저해제 및탁솔을 포함하는, 악성 종양의 치료에 사용하기 위한 약학조성물

Country Status (25)

Country Link
US (1) US7345088B2 (enExample)
EP (1) EP1443942B1 (enExample)
JP (1) JP2005506371A (enExample)
KR (1) KR20040066103A (enExample)
CN (1) CN100372539C (enExample)
AT (1) ATE382347T1 (enExample)
AU (1) AU2002363089B2 (enExample)
BR (1) BR0213410A (enExample)
CA (1) CA2461085A1 (enExample)
CO (1) CO5570672A2 (enExample)
DE (1) DE60224429T2 (enExample)
DK (1) DK1443942T3 (enExample)
EC (1) ECSP045054A (enExample)
ES (1) ES2301710T3 (enExample)
HU (1) HUP0402061A3 (enExample)
IL (2) IL161090A0 (enExample)
MX (1) MXPA04003671A (enExample)
NO (1) NO20042056L (enExample)
NZ (1) NZ532282A (enExample)
PL (1) PL367707A1 (enExample)
PT (1) PT1443942E (enExample)
RU (1) RU2317819C2 (enExample)
SI (1) SI1443942T1 (enExample)
WO (1) WO2003035081A1 (enExample)
ZA (1) ZA200402089B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
CA2356462A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2396593A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
CN100372539C (zh) 2008-03-05
RU2317819C2 (ru) 2008-02-27
EP1443942B1 (en) 2008-01-02
ZA200402089B (en) 2005-06-22
DE60224429D1 (de) 2008-02-14
CA2461085A1 (en) 2003-05-01
BR0213410A (pt) 2004-11-03
ECSP045054A (es) 2004-05-28
IL161090A (en) 2010-04-15
AU2002363089B2 (en) 2006-02-16
HK1080733A1 (en) 2006-05-04
HUP0402061A2 (hu) 2005-02-28
RU2004115337A (ru) 2005-04-20
MXPA04003671A (es) 2005-06-20
CO5570672A2 (es) 2005-10-31
PL367707A1 (en) 2005-03-07
NO20042056L (no) 2004-05-18
DK1443942T3 (da) 2008-05-19
EP1443942A1 (en) 2004-08-11
DE60224429T2 (de) 2008-12-18
SI1443942T1 (sl) 2008-08-31
CN1703226A (zh) 2005-11-30
US20050014726A1 (en) 2005-01-20
WO2003035081A1 (en) 2003-05-01
PT1443942E (pt) 2008-04-07
ATE382347T1 (de) 2008-01-15
US7345088B2 (en) 2008-03-18
IL161090A0 (en) 2004-08-31
NZ532282A (en) 2006-02-24
JP2005506371A (ja) 2005-03-03
HUP0402061A3 (en) 2007-05-29
ES2301710T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
KR100866025B1 (ko) 통증 치료를 위한 비스포스포네이트의 용도
US20090209493A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
ES2276119T3 (es) Combinacion de un inhibidor de aromatasa con un bisfosfonato.
US7345088B2 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
AU2002363089A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol
US20050209198A1 (en) Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
HK1080733B (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates,a cox-2 inhibitor and a taxol
JP2006511542A (ja) バルサルタンとｃｏｘ−２インヒビターの組み合わせ
US20070219115A1 (en) Pharmaceutical Uses of Bisphosphonates
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
MXPA06006278A (en) Pharmaceutical uses of bisphosphonates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070911

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090421

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20091112

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091112

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20090421

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I